EVOLUS, INC. Defined Contribution Plan, Cost
EVOLUS, INC. (EOLS) reported Defined Contribution Plan, Cost of $2.39 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-03-03
- EVOLUS, INC. defined contribution plan, cost for fiscal 2025 was $2.39M, a 17.99% increase from fiscal 2024.
- EVOLUS, INC. defined contribution plan, cost for fiscal 2024 was $2.02M, a 27.88% increase from fiscal 2023.
- EVOLUS, INC. defined contribution plan, cost for fiscal 2023 was $1.58M, a 104.66% increase from fiscal 2022.
- EVOLUS, INC. defined contribution plan, cost for fiscal 2022 was $773.00K, a 60.71% increase from fiscal 2021.
| Period end | Defined Contribution Plan, Cost 12 month |
|---|---|
| 2025-12-31 | $2.39M 10-K · filed 2026-03-03 |
| 2024-12-31 | $2.02M 10-K · filed 2026-03-03 |
| 2023-12-31 | $1.58M 10-K · filed 2026-03-03 |
| 2022-12-31 | $773.00K 10-K · filed 2025-03-04 |
| 2021-12-31 | $481.00K 10-K · filed 2023-03-08 |
| 2020-12-31 | $524.00K 10-K · filed 2022-03-03 |
| 2019-12-31 | $479.00K 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |